Immunotherapy Shows Promise for Difficult-to-Treat HRP Ovarian Cancer
A novel immunotherapy provided durable disease control in homologous recombination proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed.
After 3 years of follow-up, median overall survival (OS) had yet to be reached in patients who received gemogenovatucel-T (Vigil), but appeared to exceed 41 months, as compared with a median OS of 26.9 months for placebo-treated patients.
Gemogenovatucel-T is a DNA transfected autologous tumor-based immunotherapy that has three mechanisms of action: personal neoantigen education, suppression of tumor growth factor-β1 and β2, and expression of granulocyte-macrophage colony-stimulating factor in the tumor microenvironment.
Median recurrence-free survival (RFS) was almost twice as long with gemogenovatucel-T versus placebo. An analysis of restricted mean survival time (RMST) showed statistically significant improvement in OS and RFS in favor of patients who received the immunotherapy.
No grade 3/4 adverse events or treatment-related myelodysplastic syndrome or acute myeloid leukemia occurred in the study.
The 3-year follow-up data support the safety and durable efficacy of gemogenovatucel-T and justify a phase III trial of maintenance therapy comparing the immunotherapy with bevacizumab and/or niraparib in patients with HRP ovarian cancer.
Reference :
- Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic oncology. 2021 Jun 1;161(3):676-80.
- https://www.medpagetoday.com/hematologyoncology/ovariancancer/95956
ارسال به دوستان